BCR and Burkitt lymphoma: BCR activates PI3K/Akt/mTOR signaling pathways to overcome the pro-apoptotic effect of c-myc overexpression and stimulate B cell proliferation; thus, inhibition of PI3K and mTOR pathways was associated with BL cell death and increased sensitivity to chemotherapy [79–81].